Brief: Sunshine Lake Pharma Says Mixed Protamine Human Insulin Injection (30R) Obtains NMPA Marketing Approval
16/04/2026 16:28
April 16 (Reuters) - Sunshine Lake Pharma Co Ltd 6887.HK: MIXED PROTAMINE HUMAN INSULIN INJECTION (30R) PREFILLED PEN-TYPE OBTAINS CHINA NMPA MARKETING APPROVAL Further company coverage: 6887.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sunshine Lake Pharma
See all newsBrief: Sunshine Lake Pharma Says Insulin Degludec Injection, Others Obtain Marketing Approval
Brief: Sunshine Lake Pharma Expects HY Loss Attributable RMB590 Million
Brief: Sunshine Lake Pharma Says Zhang Yushuai Purchases 1.5 Million H Shares
Brief: Sunshine Lake Pharma Obtains Nmpa Approval For Insulin Degludec Injection
Brief: Sunshine Lake Pharma Says Controlling Shareholder To Increase Shareholding By Hk$300 Million-Hk$600 Million In Next Six Months